|
 |
 |
|
 |
 |
|
2 - 4 OCTOBER 2008
Perspectives in Melanoma XII
Steigenberger Kurhaus Hotel
Scheveningen/The Hague, The Netherlands
Chairs:
Alexander M.M. Eggermont, MD, PhD
Erasmus University Medical Center
Daniel Den Hoed Cancer Center
Rotterdam, The Netherlands
John M. Kirkwood, MD
University of Pittsburgh Medical Center
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania, United States
Regional Co-Chairs:
Alain Spatz, MD
Institut Gustave-Roussy
Vuillejuif, France
Nelleke Gruis, PhD
Leiden University
Leiden, The Netherlands |
This activity is presented under the auspices of the European Organization for Research and Treatment of Cancer.
|
Click
here to register
for this program |
 |
|
I N V
I T A
T I O
N |
 |
|
|
Dear Colleague,
It is with great pleasure that we invite you to join us for Perspectives in Melanoma XII. This fall’s conference, 2-4 October 2008 in Scheveningen/The Hague, The Netherlands, promises to be an outstanding educational event.
With a wealth of new data in this rapidly evolving field, Perspectives in Melanoma XII is designed to provide you with a comprehensive overview of recent advances and rigorous discussions of the most current and controversial topics in the fields of melanoma, clinical research, and contemporary therapy. Led by authorities and current investigators in the field, the program will discuss several of the most promising and important on-going clinical trials. State-of-the-art presentations by experts in molecular biology, genetics, and immunology will provide a valuable educational experience for all melanoma-related disciplines.
We also know you will enjoy Scheveningen/The Hague with its opportunities for cultural activity, entertainment, shopping, relaxation and open air pursuits. Additionally, Perspectives in Melanoma XII is preceded by the EORTC Melanoma Group Meeting, held on Wednesday, 1 October 2008. Be sure to schedule a few extra days out of the office to attend both meetings.
We look forward to welcoming you to Perspectives in Melanoma XII; your diverse perspectives and contributions add immeasurable value to this international program.
Sincerely,
Alexander M.M. Eggermont, MD, PhD
Chair
John M. Kirkwood, MD
Chair |
|
|
|
S C I
E N T
I F I
C
T O P
I C S |
|
|
|
Thursday, 2 October 2008
Session I: New insights into melanoma biology, pathogenesis and epidemiology
- Melanoma stem cells
- Role of X-chromosome in pathogenesis
- Sun tanning in Iceland: Models for understanding melanoma epidemiology
- The GenoMEL report
Session II: Impact of emerging technologies for biomarker development
- Gene profiling in melanoma
- Proteomics
- Biomarker development
- The tumor infiltrating lymphocytes report
Session III: Abstract session I
- Oral presentation of selected abstracts
Session IV: Adjuvant therapy
- New biomarkers or prognostic factors in adjuvant therapy trial design
- Update on DeCOG interferon trials
- Updated analysis and discussion of current EORTC trials
- Autoimmunity and adjuvant therapy revisited
- HLA and autoimmunity
- STAT signaling and interferon response
- Roundtable discussion: Adjuvant therapy trial design and the role of biomarker studies
Friday, 3 October 2008
Session V: Advances in staging and surgery
- AJCC staging: Preview of the factors that may change in 2009
- The sentinel node: Rotterdam criteria of tumor load and prognostic false positivity
- Biological and immunological factors within the sentinel node
- Alternative staging approaches: The role of ultrasound in prospective follow-up
Session VI: Drug resistance in melanoma
- Innovative models to determine chemoresistance
- New insights into mechanisms of drug resistance in melanoma
- Discovery of novel mechanisms of drug resistance in melanoma
Session VII: Abstract session II
- Oral presentation of selected abstracts
Session VIII: Immunotherapy
- Novel improvements in dendritic cell-based vaccines for melanoma
- Targeting novel immune regulating costimulatory molecules
- Regional immunological assessment of toll receptor agonists and cytokines
- Post chemotherapy effects and the initiation of immunity
Saturday, 4 October 2008
Session IX: Targeted therapies
- Targeting signaling pathways in melanoma
- Targeting apoptosis in melanoma
- Targeting angiogenesis in melanoma
- Epigenetic targets
Session X: Reports on important ongoing clinical trials
- Including Oblimersen, Elesclomol, Thymalfasin, Nab-paclitaxel, Temozolomide and Bevacizumab
|
|
|
|
C A L L F O R A B S T R A C T S |
|
|
Participants interested in presenting data should submit abstracts online at www.imedex.com by10 July 2008. Abstracts are subject to acceptance by the Scientific Committee.Once accepted, abstracts will be published in the final course book and scheduled for oral or poster presentation, as applicable.
Acceptance notifications and guidelines for poster presentation will be sent on 14 August 2008. Authors of accepted abstracts who have not registered will have until 17 September 2008 to do so at the rate of €399. After this date, abstracts without registered presenters will be disregarded.
Submit your abstract online at www.imedex.com.
Abstract Guidelines
- Follow the online instructions
- Abstracts must be written in English
- Accepted format: Word document format, 9 point Arial font, 500 word count limit
- Use a concise title
- List affiliations of author(s) as briefly as possible, with city, state and country
- Place an asterisk (*) before the name of the presenting author
- Use standard and well-accepted abbreviations
- When using references, use standard and well-accepted formats
- Abstract content should be single-spaced, typed in lower case and contain:
- Purpose of the study
- Summarized description of the project
- Results and conclusions
Submission Deadline: 10 July 2008
Submission Instructions
Go to www.imedex.com and click “Abstracts” |
|
|
|
W H O
S H O
U L D
A T T
E N D
? |
|
|
|
This educational activity is specifically designed for medical and surgical oncologists, dermatologists, researchers and other physicians, physicians-in-training and other healthcare professionals interested in and/or involved in the care of patients with melanoma and its consequences.
|
|
|
|
O B J
E C T
I V E
S |
|
|
|
Upon completion of this activity, attendees should be able to:
- Discuss important aspects of the biology, pathogenesis and epidemiology of melanoma
- Describe the emerging technologies for biomarker development and the potential impact of biomarkers on treatment and management of melanoma
- Incorporate findings from recent clinical trials examining the role of adjuvant therapy into daily management of patients with melanoma
- Determine the utility of the sentinel node in clinical practice
- Describe emerging concepts and progress in the role of surgery and staging of melanoma
- Describe the role of the immune system in melanoma pathogenesis and identify immunological targets for therapy
- Identify currently available and investigational targeted agents for the management of
metastatic melanoma
|
|
|
|
|
R E G
I S T
R A T
I O N |
|
|
|
Click
here
to
register
for
this
program
REGISTRATION
FEES
Discounted Physician. . . . . . . . .€399
If payment received by 31 July 2008
Regular Physician. . . . . . . . . . . €499
If payment received by 24 September 2008
Full/Onsite Physician . . . . . . . . €599
If payment received after 24 September 2008
Nurses/Residents/Fellows* . . . . .€199
*proof of eligibility must accompany registration
Pharmacists* . . . . . . . . . . . . . . €299
*proof of eligibility must accompany registration
EORTC Physician discount* . . . .€100
*proof of eligibility must accompany registration
To Register: You may register online by 24 September 2008 at www.imedex.com, by calling Imedex at +1 (678) 242 0906 or by returning the registration form in this announcement by mail or fax. If you mail the form, please keep a copy for your records. Registration confirmations will be issued before the Congress.
To qualify for special registration fees, registration and full payment must be received by Imedex by the dates specified.
EORTC members receive an additional €100 off the published registration fees. Discount is for physicians only. To receive this discount you must register by telephone. Proof of eligibility may be verified.
Payment:
To pre-register, registration and payment must be received no later than 24 September 2008. Please register onsite after this date. Contact Imedex at +1 (678) 242 0906 or visit our website at www.imedex.com to ensure the program is being held as scheduled and to confirm that the meeting is not full. Registration fees must be remitted by credit card, check, or wire transfer. Checks should be payable to Imedex. To pay via wire transfer, you must add €50 to each wire transaction to cover bank charges. Include the full name of the attendee and the name of the Congress: A030.01 E Melanoma. An attendee is not registered until full payment is received.
Registration Fee Inclusions: Registration fees include admittance to all scientific sessions, Congress materials, processing of certificates of attendance or continuing medical education, and all event functions as specified in the announcement.
Cancellation: For registration fees to be refunded, written notice of cancellation must be received by Imedex at meetings@imedex.com no later than 24 September 2008. The amount of registration fees remitted, minus a €90 administrative charge, will be refunded after the Congress. Substitutions are accepted with written notification. No refunds will be made if notice is received after 24 September 2008.
Imedex does not accept responsibility for covering travel, accommodation or any other costs incurred by registrants in the rare event that this congress should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event agenda is subject to change without notice. |
|
|
|
G E N
E R A
L
I N F
O R M
A T I
O N |
|
|
|
Congress
Location
and
Registration:
Steigenberger Kurhaus Hotel
Gevers Deynootplein 30
2586 CK The Hague, The Netherlands
Tel.: +31 (0) 70 41 62636
Fax: +31 (0) 70 41 62646
www.kurhaus.nl
Italian Participants
Fargo International Meetings & Conventions SRL has been appointed as the official agency for government authorization for Italian participants. You may contact them directly at:
Fargo International Meetings & Conventions SRL
Via Piattro Maroncelli 44/66, 50137
Firenze, Italy
Tel.: +39 055 600 555
Fax: +39 055 609 078
IMPORTANT DATES
Abstract Submission Deadline
10 July 2008
Discounted Registration Deadline
31 July 2008
Abstract Notifications Mailed
14 August 2008
Abstract Presenter Registration Deadline
17 September 2008
Regular RegistrationDeadline
24 September 2008
EORTC Melanoma Group Program
1 October 2008
Presentation Dates
2-4 October 2008
The Value
- “Nice conference – I’ll be back”
- “Very good meeting”
- “Fantastic well-organized conference”
The Clinical Impact
- 95% of attendees have changed their knowledge of screening, diagnosis, and prevention
- 100% of attendees have shared information they learned at the conference with a colleague or colleagues
- 95% of attendees would recommend this conference to someone in their
same position
Imedex is a brand and assumed name used by Imedex, LLC (hereby referred to as Imedex). Imedex is solely responsible for this agenda’s content. Although Imedex attempts to ensure that the information in our program is accurate and timely, matters and opinions discussed and/or presented with respect to clinical matters are those of the discussion participants only, and not necessarily those of Imedex. Moreover, although Imedex attempts to identify and integrate the most qualified medical professionals in our program, TO THE FULLEST EXTENT PERMITTED BY LAW, IMEDEX EXPRESSLY DISCLAIM ALL WARRANTIES, EITHER EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT OF THIRD PARTIES’ RIGHTS, AND FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO THE CONTENT PRESENTED. IMEDEX FURTHER MAKES NO REPRESENTATIONS OR WARRANTIES ABOUT THE ACCURACY, RELIABILITY, COMPLETENESS OR TIMELINESS OF THE CONTENT OR ANY MATERIAL PRESENTED.
In addition, the material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.
Neither Imedex nor any of its subsidiaries or affiliates is affiliated with or formally endorsed by a medical society.
©2008 Imedex®, LLC. All rights reserved.
Reproduction in whole or part is prohibited without prior written consent from Imedex and contributing faculty.
|
|
|
|
H
O T E
L
A C C
O M M
O D A
T I O
N S |
|
|
|
Steigenberger Kurhaus Hotel
Gevers Deynootplein 30
2586 CK The Hague, The Netherlands
Tel.: +31 (0) 70 41 62636
Fax: +31 (0) 70 41 62646
www.kurhaus.nl
In the classical building of Kurhaus Hotel past and present uniquely converge. A rich and cultural past blends with a modern interior, present-day comfort and courteous hospitality. The Kurhaus hotel is in a class of its own with a prime seashore location and sand and dunes as far as they eye can see. Also nearby is royal The Hague, a magnificent city just behind the dunes, with countless opportunities for cultural activity, entertainment, shopping, relaxation and open air pursuits every conceivable amenity is close at hand or with walking distance.
The Kurhaus Hotel is easily accessible for people travelling by car, train or airplane. You can get to the hotel from Amsterdam Airport Schiphol and from Rotterdam Airport in less than an hour and from Brussels within two hours.
For the convenience of attendees, a limited number of rooms have been reserved until 17 September 2008 at a discounted rate. Several types of rooms are available. Please see the list below.
Superior town view room . . . . . . . . €233.76 per night single use
Executive town view room . . . . . . . €288.76 per night single use
Executive sea view room . . . . . . . . €328.76 per night single use
Rates quoted include tax, service charges and breakfast. This rate is not guaranteed outside the Congress dates or after 17 September 2008.
To reserve your room please contact the Kurhaus reservations department at +31 (0)70 4162630 or visit the hotel’s website at https://reservations.ihotelier.com/onescreenGroup.cfm?hotelID=4729.
To receive the group rate, callers must identify themselves as being with the Perspectives in Melanoma XII group. Internet users must enter the meeting attendee code: MELANOMA_ATT. Reservation requests received after 17 September 2008 may not be guaranteed the group rate. |
|
|
|
O R G
A N I
Z E R |
|
|
|
|
|
©
2008 Imedex®,
LLC. |
|
